Abstract from the 14th International Athens/Springfield Symposium on Advances in Alzheimer Therapy
Tramiprosate, an oral amyloid anti-aggregation agent, shows robust cognitive efficacy in APOE4/4 homozygous ad patients: efficacy and safety analyses from two Phase 3 trials